Tagraxofusp-erzs




Tagraxofusp-erzs Overview

Tagraxofusp-erzs (trade name Elzonris) is a drug for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It was approved for use in the United States in 2018.[1] Tagraxofusp-erzs is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin.[2] The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its d...

Read more Tagraxofusp-erzs Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tagraxofusp-erzs

Recent Tagraxofusp-erzs Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Tagraxofusp-erzs
  • Solution: 1000mcg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Tagraxofusp-erzs or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA